Medullary thyroid cancer (MTC) is the third most common thyroid cancer. (Rearranged in Transformation) gene mutations are considered as one of the major drivers of MTC. Vandetanib suppresses RET activity, and has shown promise in clinical trials. Unfortunately, acquired resistance to vandetanib has been observed in MTC, although the mechanism was largely unknown. We investigated the critical role of YAP (Yes-Associated Protein) on vandetanib resistance in MTC. For this, TT cells (medullary thyroid cancer cells) were treated with vandetanib for 3 months to generate a vandetanib-resistant cell line (TT-R). We investigated the role of YAP on vandetanib-resistance in TT-R cells by performing cell proliferation and colony formation assays, and examined the antitumor effects of YAP inhibitor and vandetanib in a mouse model of xenografted MTC. The TT-R cells displayed 6-fold higher IC to vandetanib than the TT cells. Overexpression of YAP resulted in resistance to vandetanib, whereas knockdown of re-sensitized the TT-R cells to vandetanib. The YAP inhibitor synergized with vandetanib on tumor inhibition. Our results suggest that YAP plays an important role in acquired resistance to vandetanib in MTC, providing basis for combating MTC with YAP inhibitor and vandetanib.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1139/bcb-2019-0354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.
BMC Cancer
December 2024
Department of Pharmaceutical Sciences, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Background: Medullary Thyroid Carcinoma (MTC) is closely associated with mutations in the RET proto-oncogene, placing the activated RET protein at the center of MTC pathogenesis. Existing therapeutic solutions, primarily tyrosine kinase inhibitors such as selpercatinib, vandetanib, and cabozantinib, have shown moderate efficacy but are accompanied by increased risks of side effects and resistance. This study unveils a promising avenue using nonactin, a compound historically recognized for its antibacterial properties, targeting the G-quadruplex interactions within the RET proto-oncogene.
View Article and Find Full Text PDFProtein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials.
Pharmacol Res
January 2025
Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
Glioblastoma (GBM) is the most common and lethal primary brain tumor. The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.
View Article and Find Full Text PDFMolecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Cell Commun Signal
September 2024
Department of Thyroid Surgery, Zhejiang Cancer Hospital, No. 1 East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Article Synopsis
- * Standard treatment for early-stage MTC is surgery, with a 10-year survival rate over 80%, while metastatic cases face lower survival rates (10-40%) and limited effective therapies.
- * Recent advancements in targeted therapies, particularly RET inhibitors like Cabozantinib, Vandetanib, Selpercatinib, and Pralsetinib, offer new hope, though challenges such as drug resistance and side effects still complicate treatment for advanced MTC.
Brain-tumor-seeking and serpin-inhibiting outer membrane vesicles restore plasmin-mediated attacks against brain metastases.
J Control Release
November 2024
Jiangsu Key Laboratory of Neuropsychiatric Diseases Research, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China. Electronic address:
Many chemotherapeutic and molecular targeted drugs have been used to treat brain metastases, e.g., anti-angiogenic vandetanib.
View Article and Find Full Text PDFVandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma.
Front Pharmacol
May 2024
Institute for Medical Biology and Hubei Provincial Key Laboratory for Protection and Application of Special Plants in Wuling Area of China, College of Life Sciences, South-Central Minzu University, Wuhan, China.
Vandetanib is a small-molecule tyrosine kinase inhibitor. It exerts its therapeutic effects primarily in a range of lung cancers by inhibiting the vascular endothelial growth factor receptor 2. However, it remains unclear whether vandetanib has therapeutic benefits in other lung diseases, particularly asthma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!